News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
569,753 Results
Type
Article (41313)
Company Profile (121)
Press Release (528314)
Multimedia
Podcasts (74)
Webinars (14)
Section
Business (154825)
Career Advice (2468)
Deals (28189)
Drug Delivery (110)
Drug Development (73651)
Employer Resources (141)
FDA (13905)
Job Trends (12357)
News (275828)
Policy (27419)
Tag
Academia (2569)
Academic (1)
Accelerated approval (22)
Adcomms (30)
Allergies (118)
Alliances (39360)
ALS (156)
Alzheimer's disease (1634)
Antibody-drug conjugate (ADC) (262)
Approvals (14055)
Artificial intelligence (425)
Autoimmune disease (109)
Automation (29)
Bankruptcy (313)
Best Places to Work (10020)
BIOSECURE Act (17)
Biosimilars (156)
Biotechnology (87)
Bladder cancer (138)
Brain cancer (50)
Breast cancer (557)
Cancer (4184)
Cardiovascular disease (364)
Career advice (2089)
Career pathing (35)
CAR-T (242)
CDC (45)
Cell therapy (639)
Cervical cancer (26)
Clinical research (62717)
Collaboration (1272)
Company closure (4)
Compensation (580)
Complete response letters (53)
COVID-19 (2589)
CRISPR (75)
C-suite (710)
Cystic fibrosis (117)
Data (5447)
Decentralized trials (2)
Denatured (16)
Depression (124)
Diabetes (436)
Diagnostics (6008)
Digital health (33)
Diversity (7)
Diversity, equity & inclusion (39)
Drug discovery (193)
Drug pricing (162)
Drug shortages (26)
Duchenne muscular dystrophy (213)
Earnings (58455)
Editorial (52)
Employer branding (18)
Employer resources (132)
Events (80034)
Executive appointments (950)
FDA (16454)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (7)
Frontotemporal dementia (18)
Funding (1170)
Gene editing (169)
Generative AI (37)
Gene therapy (537)
GLP-1 (907)
Government (4359)
Grass and pollen (7)
Guidances (370)
Healthcare (16159)
HIV (47)
Huntington's disease (40)
IgA nephropathy (75)
Immunology and inflammation (242)
Immuno-oncology (35)
Indications (71)
Infectious disease (2827)
Inflammatory bowel disease (167)
Inflation Reduction Act (15)
Influenza (97)
Intellectual property (198)
Interviews (531)
IPO (12830)
IRA (53)
Job creations (2646)
Job search strategy (1691)
Kidney cancer (17)
Labor market (54)
Layoffs (506)
Leadership (35)
Legal (5839)
Liver cancer (87)
Longevity (9)
Lung cancer (606)
Lymphoma (336)
Machine learning (31)
Management (51)
Manufacturing (573)
MASH (164)
Medical device (10877)
Medtech (10910)
Mergers & acquisitions (16222)
Metabolic disorders (1120)
Multiple sclerosis (139)
NASH (23)
Neurodegenerative disease (287)
Neuropsychiatric disorders (78)
Neuroscience (2714)
NextGen: Class of 2025 (5574)
Non-profit (4035)
Now hiring (49)
Obesity (514)
Opinion (261)
Ovarian cancer (145)
Pain (168)
Pancreatic cancer (185)
Parkinson's disease (244)
Partnered (26)
Patents (421)
Patient recruitment (374)
Peanut (47)
People (52545)
Pharmaceutical (24)
Pharmacy benefit managers (18)
Phase I (19332)
Phase II (27556)
Phase III (21033)
Pipeline (3622)
Policy (257)
Postmarket research (2324)
Preclinical (7979)
Press Release (55)
Prostate cancer (203)
Psychedelics (50)
Radiopharmaceuticals (228)
Rare diseases (697)
Real estate (4263)
Recruiting (59)
Regulatory (20869)
Reports (30)
Research institute (2183)
Resumes & cover letters (361)
Rett syndrome (22)
RNA editing (14)
RSV (65)
Schizophrenia (137)
Series A (193)
Series B (147)
Service/supplier (5)
Sickle cell disease (89)
Special edition (16)
Spinal muscular atrophy (152)
Sponsored (37)
Startups (2875)
State (2)
Stomach cancer (17)
Supply chain (83)
Tariffs (72)
The Weekly (57)
Vaccines (897)
Venture capital (67)
Weight loss (346)
Women's health (59)
Worklife (18)
Date
Today (106)
Last 7 days (528)
Last 30 days (2159)
Last 365 days (26844)
2025 (26208)
2024 (30770)
2023 (34583)
2022 (45118)
2021 (48435)
2020 (46818)
2019 (39962)
2018 (30295)
2017 (27279)
2016 (26035)
2015 (30341)
2014 (22852)
2013 (18612)
2012 (20017)
2011 (20966)
2010 (18561)
Location
Africa (747)
Alabama (70)
Alaska (4)
Arizona (199)
Arkansas (11)
Asia (35025)
Australia (7279)
California (8780)
Canada (2787)
China (905)
Colorado (358)
Connecticut (350)
Delaware (285)
Europe (78401)
Florida (1375)
Georgia (279)
Hawaii (2)
Idaho (54)
Illinois (677)
India (52)
Indiana (441)
Iowa (16)
Japan (337)
Kansas (113)
Kentucky (28)
Louisiana (22)
Maine (57)
Maryland (1145)
Massachusetts (5975)
Michigan (268)
Minnesota (445)
Mississippi (4)
Missouri (112)
Montana (22)
Nebraska (23)
Nevada (100)
New Hampshire (71)
New Jersey (2486)
New Mexico (20)
New York (2341)
North Carolina (1119)
North Dakota (6)
Northern California (4194)
Ohio (254)
Oklahoma (10)
Oregon (30)
Pennsylvania (1779)
Puerto Rico (19)
Rhode Island (36)
South America (1004)
South Carolina (53)
South Dakota (1)
Southern California (3461)
Tennessee (133)
Texas (1422)
United States (31257)
Utah (267)
Vermont (1)
Virginia (214)
Washington D.C. (64)
Washington State (725)
West Virginia (4)
Wisconsin (73)
Wyoming (2)
569,753 Results for "celyad formally known as cardio3 biosciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives
October 6, 2025
·
7 min read
Earnings
FDA Formally Rejects Regeneron’s Eylea HD Over Manufacturing Issues
Despite the rejection, analysts saw Regeneron’s use of an alternate filler for Eylea HD as a positive development, with BMO Capital Markets noting that this could signal the end of manufacturing troubles for the franchise.
October 29, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Piramal Pharma Solutions Formalizes Partnership with IntoCell, Expanding its Payload-Linker Platform and Bioconjugate Capabilities
October 30, 2025
·
4 min read
Press Releases
Astrin Biosciences Announces Scientific Advisory Board to Advance Early Cancer Detection Leveraging AI and Proteomics
December 8, 2025
·
3 min read
Press Releases
Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting
October 8, 2025
·
3 min read
Press Releases
Iridex Corporation Receives Formal Notification of Nasdaq Listing Compliance
September 10, 2025
·
2 min read
Press Releases
Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting
October 10, 2025
·
5 min read
Press Releases
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)
December 8, 2025
·
8 min read
Celyad Oncology announces intention to terminate SEC reporting obligations
Celyad Oncology SA announces that it will voluntarily file a Form 15F with the United States Securities and Exchange Commission to terminate its SEC reporting obligations under Section 13 or Section 15 of the Securities Exchange Act of 1934, as amended.
February 8, 2024
·
4 min read
Business
Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook
Celyad Oncology (Euronext: CYAD) (the “Company”), today provides a fourth quarter 2023 business update and an outlook for 2024.
January 16, 2024
·
7 min read
1 of 56,976
Next
